Catalyst Wire Dossier Catalyst Wire Dossier

VEGF-Antisense Oligonucleotide

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VEGF-Antisense Oligonucleotide, covering 2014-05-21 to 2014-05-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma [Phase 1, Phase 2]

See pricing